Moderna and Coursera Launch Free Course on mRNA Technology

1 year ago

Companies share joint commitment to leveraging technology for STEM educationAccessible education on cutting-edge science and technology represents critical step toward…

Kalm Therapeutics Emerges From Stealth With an Oversubscribed Seed Round

1 year ago

HUNTSVILLE, AL / ACCESSWIRE / August 14, 2024 / Kalm Therapeutics is pleased to announce the $700,000 oversubscribed closing of…

Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America

1 year ago

SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE /…

ADMA Biologics Announces Partial Paydown of Revolving Credit Facility

1 year ago

Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers…

American Shared Hospital Services Announces Second Quarter 2024 Earnings Conference Call

1 year ago

Call Scheduled for Today at 6:30 PM ETSAN FRANCISCO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE…

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

1 year ago

GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage…

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

1 year ago

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC…

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

1 year ago

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,…

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

1 year ago

Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,…

Precision Optics Announces Pricing of $1.4 Million Registered Direct Offering of Common Stock

1 year ago

GARDNER, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI) (the “Company”), a leading designer and…